Relative Bioavailability of BI 207127 FF Tablets, BI 207127 FF Modified Tablets and BI 207127 TFII Tablets Administered Orally as Three Tablets (Single Dose) to Healthy Male Volunteers, an Open-label, Randomised Three-way Crossover Study.
Phase of Trial: Phase I
Latest Information Update: 13 Apr 2016
At a glance
- Drugs Deleobuvir (Primary)
- Indications Hepatitis C
- Focus Pharmacokinetics
- 04 Apr 2012 Actual patient number (18) added as reported by ClinicalTrials.gov.
- 04 Apr 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 07 Mar 2012 Planned End Date changed from 1 May 2012 to 1 Mar 2012 as reported by ClinicalTrials.gov.